Advertisement
Loading...

Theraclion SA

TCLIFPNK
Healthcare
Medical - Devices
$0.53
$0.00(0.00%)
U.S. Market opens in 11h 1m

Theraclion SA Fundamental Analysis

Theraclion SA (TCLIF) shows weak financial fundamentals with a PE ratio of -4.41, profit margin of -4.60%, and ROE of 2.39%. The company generates $0.0B in annual revenue with weak year-over-year growth of -54.45%.

Key Strengths

Cash Position10.62%
Current Ratio2.21

Areas of Concern

ROE2.39%
Operating Margin-5.24%
We analyze TCLIF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -330.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-330.0/100

We analyze TCLIF's fundamental strength across five key dimensions:

Efficiency Score

Weak

TCLIF struggles to generate sufficient returns from assets.

ROA > 10%
-49.10%

Valuation Score

Excellent

TCLIF trades at attractive valuation levels.

PE < 25
-4.41
PEG Ratio < 2
1.09

Growth Score

Weak

TCLIF faces weak or negative growth trends.

Revenue Growth > 5%
-54.45%
EPS Growth > 10%
-49.25%

Financial Health Score

Excellent

TCLIF maintains a strong and stable balance sheet.

Debt/Equity < 1
-1.97
Current Ratio > 1
2.21

Profitability Score

Weak

TCLIF struggles to sustain strong margins.

ROE > 15%
239.02%
Net Margin ≥ 15%
-4.60%
Positive Free Cash Flow
No

Key Financial Metrics

Is TCLIF Expensive or Cheap?

P/E Ratio

TCLIF trades at -4.41 times earnings. This suggests potential undervaluation.

-4.41

PEG Ratio

When adjusting for growth, TCLIF's PEG of 1.09 indicates fair valuation.

1.09

Price to Book

The market values Theraclion SA at -10.47 times its book value. This may indicate undervaluation.

-10.47

EV/EBITDA

Enterprise value stands at -2.78 times EBITDA. This is generally considered low.

-2.78

How Well Does TCLIF Make Money?

Net Profit Margin

For every $100 in sales, Theraclion SA keeps $-4.60 as profit after all expenses.

-4.60%

Operating Margin

Core operations generate -5.24 in profit for every $100 in revenue, before interest and taxes.

-5.24%

ROE

Management delivers $2.39 in profit for every $100 of shareholder equity.

2.39%

ROA

Theraclion SA generates $-49.10 in profit for every $100 in assets, demonstrating efficient asset deployment.

-49.10%

Following the Money - Real Cash Generation

Operating Cash Flow

Theraclion SA generates limited operating cash flow of $-1.11M, signaling weaker underlying cash strength.

$-1.11M

Free Cash Flow

Theraclion SA generates weak or negative free cash flow of $-1.15M, restricting financial flexibility.

$-1.15M

FCF Per Share

Each share generates $-0.02 in free cash annually.

$-0.02

FCF Yield

TCLIF converts -6.83% of its market value into free cash.

-6.83%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-4.41

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

1.09

vs 25 benchmark

P/B Ratio

Price to book value ratio

-10.47

vs 25 benchmark

P/S Ratio

Price to sales ratio

16.01

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-1.97

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.21

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

2.39

vs 25 benchmark

ROA

Return on assets percentage

-0.49

vs 25 benchmark

ROCE

Return on capital employed

-0.84

vs 25 benchmark

How TCLIF Stacks Against Its Sector Peers

MetricTCLIF ValueSector AveragePerformance
P/E Ratio-4.4129.24 Better (Cheaper)
ROE239.02%713.00% Weak
Net Margin-460.20%-42604.00% (disorted) Weak
Debt/Equity-1.970.46 Strong (Low Leverage)
Current Ratio2.214.36 Strong Liquidity
ROA-49.10%-16668.00% (disorted) Weak

TCLIF outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Theraclion SA's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-90.14%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

49.78%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

73.93%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ